Research News for 2010
-
Experts Offer Opinions on Mammography Recommendations
Experts offer opinions on the U.S. Preventive Services Task Force's controversial recommendations to breast cancer screening guidelines that were issued in November 2009.
-
FDA Recommends Removing Avastin’s Breast Cancer Indication
The FDA has recommended removing the breast cancer indication from Avastin because the medicine has not been shown to be safe and effective for that use.
-
Abdominal Fat May Increase Risk of Hormone-Receptor-Negative Disease
New research suggests that premenopausal women with a large amount of abdominal fat have a higher risk of hormone-receptor-negative breast cancer than women with less abdominal fat.
-
Circulating Tumor Cells Linked to Worse Prognosis
New studies suggest that even one circulating tumor cell in a blood sample from a woman diagnosed with breast cancer is linked to a worse prognosis.
-
Xeloda Doesn’t Seem to Reduce Recurrence Risk
A new study shows that the risk of recurrence is the same whether or not Xeloda was added to a standard adjuvant chemotherapy regimen for early-stage breast cancer with a high risk of recurrence.
-
Consider Second Opinion if HER2 Test is Negative
Research suggests that HER2 test results may not be interpreted correctly, even at expert labs.
-
Link Between Obesity and Worse Prognosis Isn’t Consistent
The analysis of several studies show the link between obesity and worse prognosis in women diagnosed with early-stage breast cancer isn't consistent.
-
Experimental Combo of Herceptin and Omnitarg Helps Treat Advanced-Stage HER2-Postitive Disease
Treatment before surgery with Herceptin and Omnitarg alone or with Taxotere benefited women diagnosed with locally-advanced or inflammatory HER2-positive breast cancer.
-
Chemo During Pregnancy Doesn’t Harm Baby
New research supports other studies that suggest that chemotherapy during pregnancy doesn't have harmful effects on the baby.
-
Real World Survival Stats for Avastin Mirror Clinical Results
Analysis shows that the real world survival statistics of women diagnosed with metastatic breast cancer and treated with chemotherapy and Avastin were similar to survival statistics of women in clinical trials looking at the same combination.
